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EXPERT OPINION
Background and rationale: Atypical antpsychotics have been sucessfully used in the
treatment of bipolar disorder (BD), either as adjunctive or as monotherapy. Quetiapine is an
atypical antipsychotic extensively used in the treatment of psychotic disorders. It has
serotonergic and dopaminergic activity and it appears to be selective for the mesolimbic and
mesocortical dopamine system. The aim of this paper was to review the recent literature on
the use of quetiapine in the treatment of BD.
Methods: The literature databases currently available online were searched for papers on
quetiapine and BD. Papers and reports published between January 1995 and June 2005 were
selected and reviewed critically.
Results: Augmentative low dose quetiapine was found to be effective in BD partially
responsive to conventional mood-stabilizers. Manic and mixed episodes have been the best
studied, and quetiapine was found to be effective either as monotherapy or as adjunctive
therapy in both randomized clinical trials and open-label studies. Data on the use of quetiapine
in bipolar depression showed a significant efficacy and high remission rates. Maintenance
data suggested a role of quetiapine as a good alternative to classical mood stabilizers in
reducing recurrence rates of BD. A few studies on the efficacy in rapid cycling BD have also
been published.
Conclusions: Quetiapine is an effective agent for the short- and long-term treatment of BD.
The mechanism of action of quetiapine as a mood stabilizer is still unknown. Some preliminary
data suggest the involvement of glutamate pathways but further studies are needed to clarify
this issue.
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Introduction
Atypical antipsychotics are useful in the management of patients with schizophrenia
and other psychotic disorders. These agents are as effective as conventional
antipsychotics, such as haloperidol or chlorpromazine, but they have a different
clinical profile in schizophrenia (ie, better efficacy on negative symptoms) and an
overall better safety profile, being associated with a lower risk of inducing
extrapyramidal side-effects (Yatham 2003).
More recently there has been increasing evidence for the utility of atypical
antipsychotics in the treatment of bipolar disorder (BD), either as adjunctive therapy
(in combination with classical mood stabilizers) or as monotherapy (Berk and Dodd
2003).
The addition of antipsychotics to mood stabilizers results in a more rapid
onset of action and in a better control of agitation and psychotic behavior during
manic episodes of BD (Alderfer and Allen 2003). However, even though
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neuroleptics are effective antimanic agents, these
compounds show little or no efficacy on depressive
symptoms (Yatham 2003). In addition, neuroleptics may
induce secondary depressive symptoms and their use in the
long-term treatment of BD is usually discouraged (Yatham
2003).
Several studies suggest that atypical antipsychotics are
effective not only in the treatment of acute mania (Tohen et
al 2000; Keck et al 2003a; Khanna et al 2003) but also in
the management of other phases of BD. Olanzapine
monotherapy is as effective as classical mood stabilizers in
the maintenance treatment of BD (Altamura et al 2004),
and the combination of olanzapine and fluoxetine as well
as olanzapine monotherapy have been found to be more
effective than placebo in the treatment of acute bipolar
depression (Tohen et al 2003). More recent studies suggest
that risperidone, aripiprazole, and quetiapine may be also
effective in the long-term maintenance treatment of BD and
in bipolar depression (Ketter et al 2004; Vieta and Goikolea
2005).
Thus, atypical antipsychotics appear to have a significant
clinical effect in any phase of the treatment of BD, but the
exact mechanism underlying their mood-stabilizing
properties is still unknown.
It has been hypothesized that the antimanic effect is
related to dopamine receptor blockade, while the anti-
depressant effect is related to the blockade of serotonin
5-HT2 receptors (Vieta 2005). However, no hypotheses exist
on the mechanism of action of atypical antipsychotics in
preventing recurrences of BD in the long-term course of
the illness.
BD shares some clinical features with schizophrenia,
and both schizophrenia and BD may have a common
biological (Manji and Lenox 2000) and/or genetic
background. It may be hypothesized that several genes
confer susceptibility to psychoses, and that the psychosis
will be phenotypically expressed as schizophrenia or BD
depending on the presence of other genetic or environmental
factors (Kasper et al 2002). On the other hand, BD has a
clinical peculiarity, which is not shared by schizophrenia or
other psychotic disorders. BD, as well as other mood
disorders, is recurrent and cyclic and the neurobiological
basis of this clinical characteristic is still not completely
unraveled.
Even though atypical antipsychotics may have similar
efficacy on BD symptoms, they appear to be heterogeneous.
Different atypical antipsychotics have different pharmaco-
dynamic, pharmacokinetic, and clinical profiles and thus
they may be indicated for different patients with BD (Vieta
and Goikolea 2005).
The aim of the present study was to review the recent
literature on the use of quetiapine in the treatment of BD
with the intent of drawing a clinical efficacy profile of this
compound for the use in BD (see Table 1). Papers on the
pharmacological properties of quetiapine were also reviewed
and commented upon.
Pharmacology
Pharmacodynamic properties
Atypical antipsychotics act by modulating different
neurotransmission systems and their pharmacological profile
implies not only the blockade of dopaminergic receptors
(Kane 1996).
Quetiapine fumarate is a dibenzothiazepine derivative
with both serotonergic and dopaminergic activity. This
compound has a moderate affinity for 5-HT2A, adrenergic
(α1), muscarinic, and histaminergic H1 receptors, a minor
affinity for dopamine D2 and 5-HT1A receptors, and very
low affinity for 5-HT2C, α2, and D1 receptors (DeVane and
Nemeroff 2001). Its pharmacological effects appear to be
selective for the mesolimbic and mesocortical dopamine
pathways, while effects on the nigrostriatal dopamine
pathway, which is involved in the induction of extra-
pyramidal side-effects (EPS), are minimal (Goldstein 1999).
For this reason quetiapine shows placebo-level incidence
of EPS, which are not dose-dependent (Arvanitis and Miller
1997). Quetiapine shows a reduced activity on dopamine
receptors of the tuberoinfundibolar system, thus preventing
the induction of hyperprolactinemia, in common with
neuroleptics and with some atypical antipsychotics
(Goldstein 1999).
The good tolerability profile of quetiapine particularly
with respect to the increase in prolactin plasma levels has
been explained also by a “dynamic” observation. The
dissociation between central and peripheral dopamine D2
receptor occupancy appears to be a major determinant of
the degree of prolactin elevation during antipsychotic
treatment at therapeutic doses. Quetiapine shows a rapid
dissociation from dopamine D2 receptors (Garver 2000) and
a lower pituitary versus striatal D2 occupancy when
compared with antipsychotics with a propensity for prolactin
elevation (Kapur et al 2002).
No relationship between quetiapine plasma levels and
clinical response was found. Thus, in clinical practice,Neuropsychiatric Disease and Treatment 2006:2(2) 141
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monitoring plasma concentration is not necessary for
adjusting the dosage (Small et al 1997).
Metabolic disturbances, including obesity, dyslipidemia,
and diabetes mellitus, are common adverse events during
antipsychotic treatment (Nasrallah and Newcomer 2004).
The mechanisms underlying these side-effects are not well
understood. It has been hypothesized that they are mediated
by the decrease in serotoninergic 5-HT2A and 5-HT2C
signaling, which influence appetite and food intake, physical
activity, and metabolic rate (Wirshing et al 1998; Melkersson
et al 2000). The report of a recent consensus development
conference on antipsychotics drugs suggests that the risks
of obesity, diabetes, and hyperlipidemia with quetiapine are
intermediate, being less than with clozapine and olanzapine,
but more than with ziprasidone and aripiprazole. Weight
gain is a relatively common side-effect with some
antipsychotics; in quetiapine monotherapy trials, the mean
weight gain was 1.8 kg after 12 weeks’ treatment (Vieta et
al 2005); during treatment with olanzapine in schizophrenic
patients, a weight gain of 4.2 kg was observed after 10 weeks
(Allison et al 1999). On the other hand, no significant weight
gain was reported for aripiprazole (Lyseng-Williamson and
Perry 2004) or ziprasidone (Keck et al 2003b).
Patients treated with quetiapine, compared with those
treated with aripiprazole or ziprasidone, are the least
susceptible to develop akathisia, while sedation is the main
side-effect of the treatment with quetiapine (Vieta and
Goikolea 2005). Moreover, this compound has not been
associated with congenital malformations in humans (FDA
Pregnancy Category C) (Ketter et al 2004).
Table 1 Summary of the main clinical studies investigating the efficacy of quetiapine as adjunctive or monotherapy in the treatment
of BD
Quetiapine Study Comparison/
Study Illness phase daily dose Add-on duration adjunctive Efficacy
Sokolski and Denson Manic or 173 ± 157mg yes retrospective study Li  Li/VP  + QTP  >  Li/VP
(2003) mixed VP
Vieta et al (2005)  Manic up to 800 mg no 12 weeks PBO QTP  >  PBO
haloperidol QTP = Li = haloperidol 
Li
Sachs et al (2004) Manic 504 mg yes 3 weeks PBO QTP + Li/DVP > PBO + Li/
Li DVP
DVP
Yatham et al (2004) Manic  100–800 mg yes 3 weeks/6 weeks PBO QTP + Li/DVP > PBO + Li/
Li DVP
DVP
Bahk et al (2004) Manic 25–200 mg yes 4 weeks VP QTP + Li/VP/Li + VP/
Li Li + CBZ > Li/VP/Li +
Li+VP VP/Li + CBZ
Li+CBZ
DelBello et al (2002) Manic or mixed  432 mg yes 6 weeks PBO QTP + DVP > PBO + DVP
DVP
Calabrese et al (2004) Depressive 300  mg or 600 mg no 8 weeks PBO QTP > PBO
Altamura et al (2003) Maintenance 157.7±157.6 mg no 12 months VP  QTP = VP = Li = gabapentin
Li
gabapentin
Pae et al (2005) Maintenance 204.1±78.1 mg yes 24 weeks VP QTP + VP/Li/CBZ/
Li topiramate >
CBZ VP/Li/CBZ/topiramate
topiramate
Abbreviations: CBZ, carbamazepine; DVP, divalproex; Li, lithium; PBO, placebo; QTP, quetiapine; VP, valproate.Neuropsychiatric Disease and Treatment 2006:2(2) 142
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Pharmacokinetic properties
After quetiapine oral administration the mean time needed
to reach maximum plasma concentrations (tmax) ranges from
1 to 1.5 hours; food intake does not modify the absorption
of quetiapine. The binding with plasma proteins is about
83%. For low doses (10–25 mg) quetiapine plasma levels
decline, with a mean apparent elimination half-life (t½)
ranging from 3.1 to 5.5 hours. For doses of 250 mg and
higher, the mean t½ is approximately 6 hours. Quetiapine is
primarily and extensively metabolized. Plasma
concentrations of the two active metabolites, 7-hydroxy-
quetiapine and 7-hydroxy-N-desalkyl-quetiapine, are about
5% and 2%, respectively, of those of quetiapine. Quetiapine
appears to be the major circulating species in plasma and
its metabolites do not contribute to the pharmacological
effects of the mother drug (DeVane and Nemeroff 2001).
The enzyme primarily responsible for the metabolism of
quetiapine is CYP3A4, while a small contribution is given
by CYP2D6 (Grimm et al 1997). Approximately 73% of
the drug is excreted in the urine and 21% in feces.
There are no gender-related differences in the
pharmacokinetics of quetiapine, and no dose adjustment is
required when treating adolescent (McConville et al 2000)
or elderly patients.
Unlike what has been shown with other antipsychotics,
quetiapine metabolism is not affected by cigarette smoking,
given that CYP1A2, the major CYP enzyme induced by
cigarette smoking, is not involved in quetiapine metabolism.
A study on a small sample (n = 8) of nonpsychotic
individuals with renal or hepatic impairment has been done
to determine the effect of these dysfunctions on quetiapine
pharmacokinetics. The changes observed in quetiapine
kinetics suggest that in patients with liver dysfunction the
standard starting dosage may be given and the dosage
escalation should be conducted with caution. No relationship
was found between renal function and quetiapine clearance
(Thyrum et al 2000).
Drug interactions
The coadministration of phenytoin (a potent inducer of
CYP3A4) and quetiapine may accelerate the metabolism of
quetiapine and reduce its efficacy; therefore in patients
receiving both drugs, increased dosages of the antipsychotic
may be required to maintain control of psychotic symptoms
(Wong et al 2001). An adjustment of quetiapine dosage is
also necessary during treatment with thioridazine, because
this drug increases the clearance of quetiapine (Potkin et al
2002). On the other hand, the coadministration of
ketoconazole, a potent inhibitor of the CYP3A4 enzyme
system, decreases quetiapine clearance.
Clinical use of quetiapine in BD
The main goals of the pharmacological management of BD
are 1) to treat manic or mixed episodes; 2) to treat depressive
episodes; 3) to avoid switching into mania during
antidepressant-treatment; and 4) to prevent relapses and
recurrences in the long term. Conventional mood stabilizers,
such as lithium and anticonvulsants, have represented the
first-choice treatment for BD (Altamura et al 2004).
However, classical mood stabilizers may have a limited
clinical efficacy during severe manic phases, bipolar
depression, or maintenance treatment, have a low therapeutic
index, and may require frequent plasma levels
determinations to avoid toxicity or adverse events (Berk
and Dodd 2005). The atypical antipsychotic quetiapine, as
augmentation therapy in BD patients with partial response
to classical mood stabilizers, was found to be effective and
well tolerated (Dunayevich and Strakowski 2000; Sajatovic
et al 2001). A retrospective study, conducted to evaluate the
effect of adjunctive quetiapine, included 16 patients with
bipolar I disorder (9 were in a mixed episode and the others
were manic) who were on monotherapy with lithium or
valproate for a minimum of 3 months prior to quetiapine
initiation. BD symptoms were evaluated using the Clinical
Global Impression Scale for severity of bipolar illness (CGI-
BP, Spearing et al 1997), at baseline and at endpoint after
quetiapine dose had been stable for at least 1 month.
Considering CGI-BP severity scores, the addition of
quetiapine resulted in a significant improvement in mania,
depression, and overall bipolar illness. Quetiapine efficacy
was particularly evident on insomnia, psychomotor
agitation, depressed mood, elevated mood, racing thoughts,
irritability, impulsivity, pressured speech, hypersexuality,
and psychosis (Sokolski and Denson 2003).
An important issue for the use of quetiapine in the
treatment of BD is the choice of the optimal dose. Manic
patients should be administered high doses in the early
phases of the treatment, and doses may be later adjusted
and reduced. On the other hand, depressed patients appear
to be responsive to lower doses (Vieta et al 2002).
Manic episodes and mixed states
Most of the data on the use of atypical antipsychotics,
including quetiapine, in BD come from studies done onNeuropsychiatric Disease and Treatment 2006:2(2) 143
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patients treated during manic or mixed episodes. To date,
olanzapine, risperidone, quetiapine, ziprasidone, and
aripiprazole have been approved for the use in bipolar mania
by the US Food and Drug Administration, while olanzapine,
risperidone, and quetiapine have been approved by the
European Medicines Agency (Vieta and Goikolea 2005).
The primary aim in the treatment of mania is to control
symptoms rapidly, minimizing side-effects. Current
guidelines recommend the use of lithium or valproate with
the addition of an antipsychotic in severe manic episodes,
while mild to moderate episodes could be treated with
monotherapy (antipsychotic, lithium, or valproate) (APA
2002).
Quetiapine was found to be an effective antimanic agent
either as monotherapy or as combination therapy in addition
to classical mood stabilizers in randomized clinical trials
and open-label studies (Keck 2005).
Two clinical trials on the effect of quetiapine
monotherapy for the treatment of acute bipolar mania have
been conducted (Bowden et al 2005; McIntyre et al 2005).
Each trial was a 12-week, multicenter, double-blind,
placebo-controlled study on bipolar I disorder patients
included during manic episodes. Patients were randomized
to be administered quetiapine (up to 800 mg/day) or placebo.
Two additional groups of subjects received lithium or
haloperidol. In a combined analysis of these studies,
quetiapine appeared to be superior to placebo in reducing
Young Mania Rating Scale (YMRS) baseline scores from
day 4 to day 84, and to be equivalent to haloperidol or lithium
in reducing YMRS scores by day 84. However, considering
tolerability profiles these agents significantly differed. The
quality of these two studies, when compared to that of
previous studies, is enhanced by the inclusion of an active
comparator in addition to placebo group (Vieta et al 2005).
The efficacy and tolerability of quetiapine as add-on
treatment was evaluated in a 3-week, double-blind, placebo-
controlled study, done on BD I (manic phase) patients.
Subjects included in the study were treated with lithium or
valproate semisodium, and were randomized to be
administered adjunctive quetiapine (up to 800 mg/day) or
placebo. Assessments included a complete medical and
psychiatric history, the administration of the YMRS and of
the CGI-BP Severity of Illness, a complete physical
examination, vital signs, weight, blood chemistry testing,
thyroid function test, and ECG. Additional treatments
allowed during the study were lorazepam, zolpidem, chloral
hydrate, or zaleplon. Reduction in YMRS scores and in CGI-
BP severity scores, from baseline to week 3, was
significantly higher in the quetiapine-treated group than in
the placebo-treated one. In addition, the number of subjects
who achieved remission at the end of the study was
significantly higher among patients who received quetiapine.
Moreover, adjunctive quetiapine did not appear to precipitate
depressive symptoms (Sachs et al 2004).
Data obtained from this study and data obtained from
another large, randomized, 6-week, double-blind study have
been analyzed jointly. Since the two studies were carried
out under identical protocols, combined analyses of data of
these 402 patients were performed. The analysis showed a
significantly greater reduction in YMRS scores and in CGI-
BP severity of illness scores in patients receiving quetiapine
plus lithium or divalproex than in those receiving lithium
or divalproex monotherapy. These results indicate that
quetiapine, when used in combination with lithium or
divalproex, is more effective in controlling manic symptoms
than either lithium or divalproex monotherapy (Yatham et
al 2004).
An open-label, 4-week study investigated the short-term
efficacy of quetiapine in addition to mood stabilizers for
the treatment of adult patients with acute manic or
hypomanic episodes during the course of BD I. This study
included 18 patients treated with quetiapine added to lithium,
valproate, lithium and valproate, or lithium and
carbamazepine. YMRS, CGI, Hamilton Rating Scale for
Depression (HDRS), and the Brief Psychiatric Rating Scale
(BPRS) were used to evaluate the efficacy of this add-on
therapy. YMRS, HDRS, BPRS, and CGI scores were
significantly reduced at the endpoint in the quetiapine add-
on groups (Bahk et al 2004).
Another study on the efficacy of quetiapine in manic or
mixed episodes has been done on 30 adolescents with BD
(Del Bello et al 2002). Subjects, treated with divalproex,
were randomized to quetiapine or placebo. At the end of
the observation period, patients assigned to quetiapine
presented with significantly lower YMRS scores and a better
response rate than patients assigned to placebo.
Depressive episodes
The efficacy of quetiapine as mood stabilizer was initially
observed in studies done on patients treated for the presence
of psychotic symptoms. A meta-analysis of data from three
clinical trials that examined the use of quetiapine in patients
with schizophrenia showed a reduction of the severity of
symptoms commonly observed also in BD, ie, anxiety,
depression, apathy, thought disturbances, motor activation,
and hostility (Borison et al 1996; Arvanitis and Miller 1997;Neuropsychiatric Disease and Treatment 2006:2(2) 144
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Small et al 1997). A 4-month, multicenter, open-label trial
that included patients with different psychotic disorders
randomized to quetiapine or risperidone, suggested the
utility of quetiapine for the management of depressive
symptoms (Sajatovic et al 2002). Purdon and colleagues
(Purdon et al 2001) showed that quetiapine, when compared
with haloperidol, was more effective in reducing depressive
symptoms in schizophrenic patients.
The effect of quetiapine on depressive symptoms is
supported by the results of a large, multicenter, randomized,
double-blind, placebo-controlled trial that assessed the
efficacy of quetiapine monotherapy in subjects with DSM-
IV diagnosis of BD I or BD II. A total of 542 patients, with
moderate or severe bipolar depression (based on the
Montgomery-Asberg Depression Rating Scale [MADRS]
scores), were randomized to receive quetiapine (300 mg or
600 mg/day) or placebo for 8 weeks. At week 1 quetiapine-
treated patients showed a significant improvement on
MADRS total score when compared with placebo-treated
patients. This improvement in depressive symptoms
continued throughout the treatment period, until the end of
the study. Similar results were observed when analyzing
HDRS scores. The clinical response and the rates of
remission were also significantly higher in the group of
patients treated with quetiapine (Calabrese et al 2004).
Moreover, “core” depressive symptoms, anxiety symptoms,
and suicidal ideation were also improved during quetiapine
treatment (Calabrese et al 2004; Macfadden et al 2004).
Maintenance treatment
To date, less data are available on the use of atypical
antipsychotics in the maintenance therapy of BD than on
the use of these compounds in the treatment of manic or
mixed episodes. However, several open-label and double-
blind trials suggest that atypical antipsychotics may reduce
relapse and recurrence rates during long-term therapy, either
alone or in combination with conventional mood stabilizers.
The two monotherapy studies that led to the approval of
the use of quetiapine in acute mania were of 12 weeks’
duration (Vieta et al 2005). This treatment period was long
enough to allow for a more sustained assessment of efficacy,
particularly in terms of evaluating remission and response
rates (Vieta and Goikolea 2005). Another study, although
preliminary, considered longer treatment duration and thus
it may be considered the first long-term study on the use of
quetiapine monotherapy in BD. In this study, 28 BD
outpatients were included and followed up for 12 months
(Altamura et al 2003). Subjects were randomly assigned to
quetiapine or to a classical mood-stabilizer (valproate,
lithium, or gabapentin) and were assessed at baseline and
every 2 months until the end of the study. Assessment
included the administration of BPRS, CGI, YMRS, and
HDRS. Considering both psychopathology and global
functioning measures, quetiapine appeared to have an
efficacy comparable to that of conventional mood stabilizers,
with a favorable tolerability profile.
In another open-label study, patients with BD I were
treated with quetiapine, in combination with standard
therapy, for a period of 76 weeks. The addition of quetiapine
induced a significant reduction in the relative risk of
developing manic or depressive relapses (Carta et al 2004).
An additional study evaluated the efficacy of quetiapine
as adjunctive therapy in the long-term treatment for bipolar
mania. The study was done on 23 patients with BD I, and
the clinical evaluation included the administration of YMRS,
CGI, and HDRS and was done at baseline and at weeks 1,
4, 12, and 24 (endpoint). The significant reductions of the
YMRS, CGI, and HDRS scores pointed out the efficacy of
add-on quetiapine in the long-term treatment of BD (Pae et
al 2005).
Rapid cycling BD
Patients with a rapid-cycling course of BD usually show
poor or no response to classical mood stabilizers (Calabrese
et al 2001). The main goal of pharmacological treatment in
rapid- cycling BD patients is to reduce the cycle frequency
and to improve the long-term outcome (Vieta 1999). The
clinical guidelines of the American Psychiatric Association
endorse the use of mood stabilizer plus antipsychotic
combinations as first-line treatment in subjects with severe
rapid-cycling disease (APA 2002). However, few studies
exist on the efficacy of pharmacotherapy on the long-term
course of rapid-cycling BD, and polypharmacy is often the
only way to obtain euthymia (Post et al 1998).
A small open-label study was done on 14 rapid-cycling
BD patients treated with add-on quetiapine to the original
psychotropic regimen of each patient. The concomitant
treatments were benzodiazepines, antidepressants (ie,
venlafaxine, paroxetine, clomipramine, or mirtazapine) or
mood-stabilizers (ie, lithium, valproate, carbamazepine). At
the beginning of the study 5 subjects were manic, 2 were
hypomanic, 1 was euthymic, 3 were depressed, and 3 were
in a mixed state. Patients were followedup for 112 ± 33 days
and the efficacy of quetiapine addition was evaluated usingNeuropsychiatric Disease and Treatment 2006:2(2) 145
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the CGI-BP, YMRS, and HDRS. An overall improvement
of 2 of the 3 CGI-BP subscales (the general subscale and
the manic subscale) and of the YMRS was observed. This
result suggests that quetiapine may be an effective treatment
for rapid-cycling BD patients (Vieta et al 2002).
Another open-label study, conducted by Ghaemi and
colleagues (Ghaemi et al 2002), showed the efficacy and
tolerability of quetiapine in 16 rapid-cycling BD subjects.
In this study both mania and depressive scores decreased
significantly from baseline to the end of the observation
period.
Quetiapine-induced mania
An important consideration when treating patients with BD
is the risk of inducing switching into mania or hypomania.
The pathogenesis of drug-induced mania in BD is complex,
probably including also genetic susceptibility factors.
However, the phenomenon is a serious complication of BD
treatment both in the short- and in the long-term management
of the illness (Mundo et al 2001). Despite the fact that several
studies have shown that quetiapine is effective in controlling
acute mania, there are some recent case reports of manic
symptoms associated with quetiapine treatment (Biancosino
et al 2003; Lykouras et al 2003; Pacchiarotti et al 2003). As
has been hypothesized for risperidone-induced mania, the
switching may be caused by high 5-HT2A/D2 receptor
occupancy (Lane et al 1998; Richelson 1999; Schmidt et al
2001), even though individual susceptibility factors cannot
be excluded and rather are likely to play a substantial role.
It is worth mentioning that all cases with mania or
hypomania induced during quetiapine treatment remitted
soon after quetiapine dose reduction (Rachid et al 2004).
Conclusions
Published data on the use of quetiapine in BD show that it
is a safe and effective compound for the treatment of acute
episodes, as either augmentative therapy or monotherapy.
Most of the studies have pointed out the comparable efficacy
of quetiapine on manic or mixed episodes to that of classical
mood stabilizers, with the advantage of a better tolerability
profile and a higher therapeutic index. More recent data on
the use of quetiapine monotherapy (Calabrese et al 2004)
in the treatment of bipolar depressive episodes appear to be
more interesting. These data, although promising, need
further replication on additional samples.
Controlled studies on the use of quetiapine monotherapy
in the maintenance treatment of BD are still few.
It has been shown that quetiapine is as effective as
valproate, lithium, or gabapentin in reducing recurrence rates
in BD episodes, with an overall better tolerability.
Quetiapine, as well as other atypical antipsychotics such
as olanzapine, appear to have a specific effect on BD
compared with neuroleptics. Neuroleptics have a proven
effect on manic symptoms (Bourin et al 2005; Smulevich et
al 2005) but no positive effects on depressive episodes
(Altamura 1996; Bourin et al 2005) or on the prevention of
recurrences (Esparon et al 1986). On the other hand, atypical
compounds (ie, olanzapine, quetiapine) have been shown
to act on any phase of BD and also on the long-term
maintenance phase of the illness (Altamura et al 2003, 2004).
The mechanism of action of atypical antipsychotics as
antimanic or antidepressant agents has been explained by
the fact that these compounds block dopamine D2 and
serotonin 5-HT2 receptors. These pharmacological
properties have been associated with the antimanic and the
antidepressant effects, respectively (Vieta 2005). Moreover,
these two receptor subtypes have been implicated in the
pathogenesis of quetiapine-induced manic switches reported
in a few case reports (Biancosino et al 2003; Lykouras et al
2003; Pacchiarotti et al 2003).
However, the mechanism of action of quetiapine or
olanzapine as long-term mood stabilizers in preventing
recurrences of BD is still unknown.
With respect to the pharmacological properties of these
two compounds, it has been shown by preclinical studies
that olanzapine and quetiapine, but not typical anti-
psychotics, may have an effect on the expression of
glutamate receptors. Chronic administration of quetiapine,
but not of haloperidol, reduces the expression of ionotropic
and metabotropic glutamate receptors in rat brain,
particularly in the nucleus accumbens (Tascedda et al 1999).
In addition, chronic olanzapine administration up-regulates
glutamate AMPA receptors in the frontal cortex of rat brain,
while haloperidol has no effect (Tascedda et al 2001). More
recently, clinical studies on schizophrenia patients have
shown that the treatment with some atypical antipsychotics
(ie, quetiapine, olanzapine, risperidone, sertindole) induces
an increase in glutamate plasma levels that is not correlated
with the clinical antipsychotic response (van der Heiden et
al 2004). What makes these studies interesting for the
understanding of the possible mechanisms of action of
atypical antipsychotics as long-term mood stabilizers in BD
is that the glutamate system has been implicated in the
pathogenesis of BD itself. This evidence comes from someNeuropsychiatric Disease and Treatment 2006:2(2) 146
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genetic studies suggesting that polymorphisms of the
glutamate receptor genes are implicated in the pathogenesis
of BD (Mundo et al 2003). In addition, the neurobiological
model of recurrence for mood disorders, including BD,
involves glutamate receptors (Post & Weiss 1999).
The hypothesis that atypical antipsychotics act as mood
stabilizers through their effect on the glutamate system, and
the intriguing convergence of data on the potential
involvement of glutamate in the pathogenesis of BD, warrant
new biological and clinical research in the field.
Finally, data on the significant clinical effect of
quetiapine in reducing recurrence rates in rapid cycling BD,
although preliminary, appear to be interesting.
In conclusion, the efficacy of quetiapine in treating
different phases of BD has been supported by several studies,
even though for some of them further replications and more
detailed results are needed.
Further studies should investigate the relationship
between quetiapine dose and antidepressant response
together with the effect of quetiapine not only on “core”
depressive symptoms but also on anxiety symptoms and on
suicidal ideation. In addition, it would be useful to
investigate specifically the potential effects of atypical
antipsychotics, including quetiapine, in reducing or
increasing manic switch rates. When treating bipolar
depression the use of antidepressant monotherapy is
considered a risk factor for antidepressant-induced mania,
and mood stabilizers have been found to be protective with
respect to this side-effect (Mundo et al 2006). However,
there are no controlled studies investigating differences or
similarities between atypical antipsychotics and classical
mood stabilizers in preventing induction of manic switches
or rapid-cycling course in bipolar patients.
Also, future studies on clinical subtypes of BD
characterized by high rates of comorbidities, worse outcome,
and poor response to classical mood stabilizers are needed,
as well as studies aimed at defining the specific profile of
BD patients who may preferentially respond to atypical
antipsychotics and quetiapine.
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